Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]
Please note the following on from information provided to NICE by the company in November 2013, the appraisal of Denosumab for preventing bone metastases in castrate resistant prostate cancer [ID405] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 405
Referral date 01 November 2011
Topic area
  • Cancer
  • Urogenital

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: Alice Law
Executive Lead: TBC
Project manager:

Lori Farrar

Technical Lead: Richard Diaz

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
23 January 2023 Discontinued. Please note the following on from information provided to NICE by the company in November 2013, the appraisal of Denosumab for preventing bone metastases in castrate resistant prostate cancer [ID405] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
28 November 2013

The Institute has now been informed by the manufacturer that it will no longer be pursuing a licensing application for denosumab in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

17 April 2013 The manufacturer of Denosumab has informed NICE that they will not provide a submission for this appraisal. NICE has therefore suspended this appraisal.

For further information on our processes and methods, please see our CHTE processes and methods manual